William Durrett, MD
Interventional Pain Medicine · Aiken, SCNPI 1215946538
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 288 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by Abbott at 29.6% of the total. Reporting peaked in 2019 at $2,208 and has fallen 86.4% since, to $300 in 2025.
Across 288 payments — averaging $28.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Forte Bio-pharma LLC$903
- Flowonix Medical Incorporated$726
- Nevro Corp.$518
- Arbor Pharmaceuticals, Inc.$517
- AbbVie$468
- plus $3K from 31 others
What the payments were for
- Food & beverage$8,257100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolate$2,509
- Nalocet$812
- Prometra II$653
- PROCLAIM$363
- Senza Spinal Cord Stimulation System$243
- Quattrode Leads SCS Leads$159
- ETERNA$143
- Octrode SCS Leads$133
- DSUVIA$123
- Proclaim IPG$115
- Neuromodulation Dspsbls and Accs$114
- Proclaim Family of SCS IPGs$109
- RESTORE$101
How this compares
$8,278 in reported general payments places this provider in the 80th percentile of 38 interventional pain medicine providers in South Carolina.
See all interventional pain medicine providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 115 | $62,030 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,467 | $52,137 |
| BelbucaBuprenorphine Hcl | 79 | $45,270 |
| UbrelvyUbrogepant | 15 | $41,204 |
| HorizantGabapentin Enacarbil | 59 | $34,682 |
| OxycontinOxycodone Hcl | 59 | $29,601 |
| RelistorMethylnaltrexone Bromide | 12 | $28,678 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 716 | $28,001 |
| NucyntaTapentadol Hcl | 22 | $26,900 |
| Nurtec OdtRimegepant Sulfate | 12 | $18,345 |
| Buprenorphine | 85 | $17,406 |
| Tramadol Hcl ErTramadol Hcl | 283 | $15,379 |
| Hysingla ErHydrocodone Bitartrate | 38 | $13,168 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $12,690 |
| ZtlidoLidocaine | 26 | $12,268 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta, Nucynta Er | $141 | $142,801228 claims |
| AbbVieUbrelvy | $468 | $41,20415 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $517 | $34,68259 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $114 | $28,67812 claims |
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate | $54 | $18,456122 claims |
| PfizerNurtec Odt | $335 | $18,34512 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $260 | $12,26826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 38 interventional pain medicine providers in South Carolina.
Other interventional pain medicine in Aiken
- Phillip SuwanAiken$6K
- Mark NethertonMt Pleasant$102K
- Marion McMillanSeneca$89K
- Jason RosenbergMurrells Inlet$82K
- Ryan NoblesMt Pleasant$43K
- Justin HutchesonGreenville$23K
- Joshua BighamSpartanburg$14K
- David RoweBluffton$9K
- Kenneth GrosslightWest Columbia$7K
- William RichardsonMt Pleasant$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.